Alcyone Therapeutics
Dr. Mehrotra has over 25 years of biotechnology equity research, investment banking, strategy and executive team operational experience. He previously held leadership roles at Evercore ISI, MTS Health Partners, Ovascience, Credit Suisse and Cowen. Dr. Mehrotra holds a B.S. and a Ph.D. in biochemistry and molecular biology from The Wellcome Trust Center.
This person is not in any offices
Alcyone Therapeutics
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1).